Closing remarks and Outlook

Closing Remarks.

Closing Remarks.

About twenty years ago, the leaders of the National Cancer Institute (NCI) decided to start a new branch in the Clinical Oncology Program of the Division of Cancer Treatment. That new entity was named the Clinical Pharmacology Branch (CPB), and its first leader was a brilliant, young, promising investigator named Bruce A. Chabner. Chabner was educated at Yale and Harvard, and appeared to have a...

Closing remarks

DMARDs = disease-modifying antirheumatic drugs; NSAIDs = non-steroidal anti-inflammatory drugs; RA = rheumatoid arthritis; TNF = tumor necrosis factor. Introduction The past decade has been marked by significant advances in rheumatology, including a better understanding of the pathophysiology of rheumatic diseases and the addition of agents to the therapeutic armamentarium. Studies in cell biol...

Closing Remarks

Well we’ve had a rich and interesting day. I can’t possibly do it justice. But I have been asked to make a few minutes of final remarks. I assure you this was not my idea. And by my clock, I have minus eight minutes. So I’ll try to be very quick. But my assignment as I understood is it to try and extract from today’s presentations and discussions and the posters some discernable themes in the w...

Closing remarks.